7:01AM Seattle Genetics achieves $5 mln milestone under millennium collaboration for European medicines agency acceptance of brentuximab vedotin MAA (SGEN) 20.70 : Co announces that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRISTM) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The milestone was triggered by the European Medicines Agency acceptance of the Marketing Authorization Application for brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.
Market Data 
Markets 
AI
